Pyrido[4,3-B]indoles and methods of use

1. A method of treating a cognitive disorder or a disorder characterized by causing at least one symptom associated with impaired cognition, wherein the cognitive disorder or disorder characterized by causing at least one symptom associated with impaired cognition is schizophrenia, comprising administering to an individual in need thereof an effective amount of a compound of the formula (A):

wherein:

R 1 is H, hydroxyl, nitro, cyano, halo, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, perhaloalkyl, acyl, acyloxy, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, C 1 -C 8 perhaloalkoxy, alkoxy, aryloxy, carboxyl, thiol, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl or carbonylalkylenealkoxy;

R 2 is H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

X is OH, H, C 1 -C 8 unsubstituted alkyl or is taken together with Y to form a cyclic moiety of the formula —OCH 2 CH 2 O—;

Y is halo, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C i -C 8 alkyl substituted with a carbonylalkoxy, carboxyl or acylamino moiety or is taken together with X to form a cyclic moiety of the formula —OCH 2 CH 2 O—; and

R 3 is a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkenyl or substituted or a unsubstituted heterocyclyl

or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has X is OH and Y is an unsubstituted aryl.

3. The method of claim 2 , wherein the compound is of the formula (I):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

4. The method of claim 3 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 and R 2 are independently an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is a substituted aryl or unsubstituted heteroaryl.

5. The method of claim 4 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

6. The method of claim 4 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

7. The method of claim 4 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is a substituted phenyl, or unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

8. The method of claim 1 , wherein the compound is of the formula (II):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

9. The method of claim 8 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is an unsubstituted C 1 -C 8 alkyl, R 2 is H, an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl.

10. The method of claim 9 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

11. The method of claim 9 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

12. The method of claim 9 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is a substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

13. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has X is H and Y is a C 1 -C 8 alkyl substituted with a carbonylalkoxy, carboxyl or acylamino moiety.

14. The method of claim 13 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has Y is a moiety selected from the structures:

where R 4 is a C 1 -C 8 unsubstituted alkyl.

15. The method of claim 14 , wherein the compound is of the formula (III):

and wherein R 1 , R 2 and R 3 are as defined for formula (A) and R 4 is an unsubstituted C 1 -C 8 alkyl,

or a pharmaceutically acceptable salt or solvate thereof.

16. The method of claim 15 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is an unsubstituted C 1 -C 8 alkyl, R 2 is an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is a substituted aryl or a substituted or unsubstituted heteroaryl.

17. The method of claim 16 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

18. The method of claim 16 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

19. The method of claim 16 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is a substituted phenyl, or a substituted or unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

20. The method of claim 14 , wherein the compound is of the formula (IV):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

21. The method of claim 20 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is an unsubstituted C 1 -C 8 alkyl, R 2 is an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is a substituted aryl or a substituted or unsubstituted heteroaryl.

22. The method of claim 21 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

23. The method of claim 21 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

24. The method of claim 21 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is a substituted phenyl, or a substituted or unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

25. The method of claim 14 , wherein the compound is of the formula (V):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

26. The method of claim 25 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is an unsubstituted C 1 -C 8 alkyl, R 2 is an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is a substituted aryl or a substituted or unsubstituted heteroaryl.

27. The method of claim 26 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

28. The method of claim 26 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

29. The method of claim 26 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is a substituted phenyl, or a substituted or unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

30. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has X is an H or an unsubstituted C 1 -C 8 alkyl and Y is halo.

31. The method of claim 30 , wherein the compound is of the formula (VI):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

32. The method of claim 31 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is an unsubstituted C 1 -C 8 alkyl, R 2 is an unsubstituted C 1 -C 8 alkyl or halo, and R 3 is an unsubstituted heteroaryl.

33. The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

34. The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl or chloro.

35. The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is an unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

36. The method of claim 30 , wherein the compound is of the formula (VII):

and wherein R 1 , R 2 and R 3 are as defined for formula (A),

or a pharmaceutically acceptable salt or solvate thereof.

37. The method of claim 30 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 and R 2 are independently an unsubstituted C 1 -C 8 alkyl and R 3 is an unsubstituted heteroaryl.

38. The method of claim 37 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 1 is methyl.

39. The method of claim 37 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 2 is methyl.

40. The method of claim 37 , wherein the compound, or a pharmaceutically acceptable salt or solvate thereof, has R 3 is an unsubstituted pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.

41. A method of treating a cognitive disorder or a disorder characterized by causing at least one symptom associated with impaired cognition, wherein the cognitive disorder or disorder characterized by causing at least one symptom associated with impaired cognition is schizophrenia, comprising administering to an individual in need thereof an effective amount of a compound selected from the group consisting of:

2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indo-5(2H)-yl)-1-(4-fluorophenyl)-1-phenylethanol;

2,8-Dimethyl-5-((2-phenyl-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

5-((2-(4-Fluorophenyl)-1,3-dioxolan-2-yl)methyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-((2-(4-fluorophenyl)-1,3-dioxolan-2-yl)methyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-((2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

Ethyl 4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-fluorophenyl)butanoate;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-fluorophenyl)butanoic acid;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-fluorophenyl)-N-methylbutanamide;

5-(2-Fluoro-2-(pyridin-4-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-(2-fluoro-2-(pyridin-4-yl)propyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-phenyl-1-(pyridin-4-yl)EtOH;

2-Methyl-5-((2-(pyridin-4-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

2,8-Dimethyl-5-((2-(pyridin-3-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

5-((2-(2,4-Difluorophenyl)-1,3-dioxolan-2-yl)methyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

2,8-Dimethyl-5-((2-(pyrimidin-4-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-((2-(2-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-2-methyl-5-((2-(2-methylpyridin-4-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-((2-(2-fluorophenyl)-1,3-dioxolan-2-yl)methyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-2-methyl-5-((2-(6-methylpyridin-3-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-2-methyl-5-((2-(3-methylpyridin-4-yl)-1,3-dioxolan-2-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-((2-(4-methoxyphenyl)-1,3-dioxolan-2-yl)methyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

Isopropyl 4-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-methoxyphenyl)butanoate;

Isopropyl 4-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-chlorophenyl)butanoate;

Isopropyl 4-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(6-methylpyridin-3-yl)butanoate;

tert-Butyl 4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-fluorophenyl)butanoate;

Methyl 3-(2,4-difluorophenyl)-4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)butanoate;

Ethyl 4-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(3-methylpyridin-4-yl)butanoate;

Ethyl 4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol5(2H)-yl)-3-(pyridin-4-yl)butanoate;

Ethyl 4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(pyridin-3-yl)butanoate;

Ethyl 4-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(pyrimidin-4-yl)butanoate;

Ethyl 4-(2-ethyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol5(2H)-yl)-3-(2-methylpyridin-4-yl)butanoate;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(pyridin-4-yl)butanoic acid;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(pyridin-3-yl)butanoic acid;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(pyrimidin-4-yl)butanoic acid;

4-(2-Ethyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(2-methylpyridin-4-yl)butanoic acid;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(6-methylpyridin-3-yl)butanoic acid;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(2-fluorophenyl)butanoic acid;

3-(2,4-Difluorophenyl)-4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)butanoic acid;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(3-methylpyridin-4-yl)butanoic acid;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-methoxyphenyl)butanoic acid;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-chlorophenyl)butanoic acid;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(pyridin-4-yl)butanamide;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(pyridin-3-yl)butanamide;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(pyrimidin-4-yl)butanamide;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(2-methylpyridin-4-yl)butanamide;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(6-methylpyridin-3-yl)butanamide;

4-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(2-fluorophenyl)-N-methylbutanamide;

3-(2,4-Difluorophenyl)-4-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methylbutanamide;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-N-methyl-3-(3-methylpyridin-4-yl)butanamide;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-methoxyphenyl)-N-methylbutanamide;

4-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-(4-chlorophenyl)-N-methylbutanamide;

5-(2-Fluoro-2-(4-fluorophenyl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-(2-(2,4-difluorophenyl)-2-fluoropropyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

5-(2-(4-Chlorophenyl)-2-fluoropropyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-(2-fluoro-2-(pyridin-3-yl)propyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

2-Ethyl-5-(2-fluoro-2-(pyridin-3-yl)propyl)-8-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

5-(2-Fluoro-2-(pyrimidin-4-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-(2-fluoro-2-(6-methylpyridin-3-yl)propyl)-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

5-(2-Fluoro-2-(2-methylpyridin-4-yl)propyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

2-Cyclopropyl-5-(2-fluoro-2-(4-methoxyphenyl)propyl)-8-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;

8-Chloro-5-(2-fluoro-2-(3-methylpyridin-4-yl)propyl)-2-isopropyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; and

5-(2-Fluoro-2-(pyridin-4-yl)ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole,

or a pharmaceutically acceptable salt thereof.